Methylprednisolone
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Methylprednisolone: Alopecia mucinosa
One-Sentence Summary
Methylprednisolone is a systemic and injectable corticosteroid with an anti-inflammatory and immunosuppressive action, and it is marketed in Canada. The TxGNN model predicts it may be effective for alopecia mucinosa, with a score of 0.9999. No clinical trials and no publications directly support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 14 of 14) |
| Number of DINs | 14 (marketed: 14) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on general knowledge, methylprednisolone is a glucocorticoid, a class that suppresses inflammatory and immune activity. Mechanistically it may be applicable to inflammatory skin and hair-follicle conditions.
For alopecia mucinosa (also called follicular mucinosis), a plausible rationale is an anti-inflammatory effect on the inflammatory infiltrate around the hair follicle. The data compiled for this report do not test or confirm this idea.
The very high score appears to reflect the model’s recognition that this condition resembles other hair-loss disorders. It is not backed by trial or literature evidence. The prediction should therefore be treated as a hypothesis to examine, not as an established benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Methylprednisolone is currently marketed in Canada, and all recorded licences are valid products. The main authorizations are:
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00030759 | DEPO-MEDROL | Not listed | Not listed |
| 00030678 | SOLU-MEDROL | Not listed | Not listed |
| 00036129 | MEDROL | Not listed | Not listed |
| 02367971 | SOLU-MEDROL | Not listed | Not listed |
| 00260428 | DEPO-MEDROL WITH LIDOCAINE | Not listed | Not listed |
Safety Considerations
Drug Interactions: Interaction screening returned 100 recorded interactions. The two classified as Major are:
- Bupropion
- Clarithromycin
Many Moderate interactions were also recorded, notably with antidiabetic agents (for example metformin, pioglitazone, acarbose, alogliptin, canagliflozin, dapagliflozin, empagliflozin, dulaglutide, saxagliptin and chlorpropamide). Other Moderate interactions include amphotericin B, aprepitant, acetylsalicylic acid and bisacodyl. Zinc sulfate is classified as Minor.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but no clinical trials or publications address alopecia mucinosa. The evidence level is therefore L5, model prediction only.
To proceed, the following is needed:
- Published clinical studies or case series on corticosteroid use in alopecia mucinosa
- Mechanism of action data for methylprednisolone
- Package insert warnings and contraindications to complete the safety review
- Assessment of which route of administration would suit the condition (for example systemic, intralesional or topical) against the marketed products
- A review of the drug interactions and long-term systemic steroid risks for the likely patient population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.